Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INR101 PET/CT for Pelvic Lymph Node Metastasis in Prostate Cancer
NCT06922903Phase 3Not yet recruiting
- Sponsor
- Yunhe Pharmaceutical
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of INR101 in prostate cancer (PCa), sponsored by Yunhe Pharmaceutical. Primary endpoints: Sensitivity of INR101 PET/CT in detecting pelvic lymph node metastasis and Specificity of INR101 PET/CT in detecting pelvic lymph node metastasis. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
INR101
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06922903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922903.